NEW YORK — Cyted Health, a developer of gastrointestinal cancer molecular diagnostics, said last week that it has raised $44 million in a Series B financing round.

纽约——胃肠道癌症分子诊断开发商Cyted Health上周表示，已在B轮融资中筹集了4400万美元。

The round was co-led by EQT Life Sciences, Advent Life Sciences, and British Business Bank, with participation from existing investors Morningside and BGF.

本轮融资由EQT生命科学、Advent生命科学和英国商业银行共同领投，现有投资者晨兴资本和BGF参与。

Cyted offers a swallowable capsule-based device, called EndoSign, that is used to collect esophageal cells for analysis and was cleared by the US Food and Drug Administration in early 2024. The UK-based company is also

Cyted提供了一种可吞咽的胶囊式设备，称为EndoSign，用于收集食道细胞进行分析，并于2024年初获得美国食品和药物管理局的批准。这家总部位于英国的公司还

developing

开发

a molecular test for Barrett's esophagus and esophageal cancer that uses the device.

使用该设备进行巴雷特食管和食管癌的分子检测。

Cyted said that it will use the Series B funding to accelerate its commercial operations in the US, consolidate its commercial activities in the UK, and expand its diagnostics portfolio.

Cyted表示，将利用B轮融资加速其在美国的商业运营，巩固其在英国的商业活动，并扩展其诊断产品组合。

Cyted previously raised £7.5 million ($10.1 million) in early 2020.

Cyted在2020年初曾筹集了750万英镑（1010万美元）。